References
1.
Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655–2664.
2.
Hadi S, Zhang L, Hird A, de Sa E, Chow E: Validation of symptom clusters in patients with metastatic bone pain. Curr Oncol 2008;15:211–218.
3.
Zuetenhorst JM, Hoefnageli CA, Boot H, Valdés Olmos RA, Taal BG: Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735–741.
4.
Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH: Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 2003;44:184–191.
5.
Hlatky R, Suki D, Sawaya R: Carcinoid metastasis to the brain. Cancer 2004;101:2605–2613.
6.
Lombard-Bohas C, Mitry E, O’Toole D, Louvet C, Pillon D, Cadiot G, Borson-Chazot F, Aparicio T, Ducreux M, Lecomte T, Etienne PL, Cacheux W, Legoux JL, Seitz JF, Ruszniewski P, Chayvialle JA, Rougier P, FFCD-ANGH-GERCOR: Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 2009;89:217–222.
7.
Zuetenhorst JM, Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123–131.
8.
Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–690.
9.
Ross EM, Roberts WC: The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 1985;79:339–354.
10.
Taal BG, Visser O: Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80:3–7.
11.
Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS: Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics 2006;26:41–58.
12.
Khan JH, McElhinney DB, Rahman SB, George TI, Clark OH, Merrick SH: Pulmonary metastases of endocrine origin: the role of surgery. Chest 1998;114:526–534.
13.
Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–959.
14.
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5–21.
15.
Scarsbrook AF, Ganeshan A, Statham J, Thakker RV, Weaver A, Talbot D, Boardman P, Bradley KM, Gleeson FV, Phillips RR: Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 2007;27:455–477.
16.
Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008;87:8–19.
17.
Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, Kaltsas G, Kelestimur F, Kvols L, Scoazec JY, Garcia MI, Caplin ME, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008;87:31–39.
18.
Plöckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 2008;87:20–30.
19.
Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, Jensen R, Kos-Kudła B, Öberg K, O’Connor JM, Pavel ME, Vullierme MP, Frascati Consensus Conference participants: Poorly differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008;87:40–46.
20.
Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O’Toole D, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008;87:47–62.
21.
Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, Sevilla Garcia MI, Knapp WH, Keleştimur F, Sauvanet A, Pauwels S, Kwekkeboom DJ, Caplin M, Frascati Consensus Conference participants: Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212–215.
22.
Falconi M, Plöckinger U, Kwekkeboom DJ, Manfredi R, Körner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmüller T, Öberg K, Scoazec JY, Frascati Consensus Conference participants: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006;84:196–211.
23.
Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Wolf O, Bechstein WO, Christ E, Taal BG, Knigge U, Ahlman H, Kwekkeboom DJ, O’Toole D, Frascati Consensus Conference participants: Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology 2006;84:165–172.
24.
Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O’Connor JM, Pauwels S, Kloppel G, Frascati Consensus Conference, European Neuroendocrine Tumor Society: Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006;84:173–182.
25.
Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, Pauwels S, Kwekkeboom DJ, Rindi G, Frascati Consensus Conference, European Neuroendocrine Tumor Society: Well differentiated gastric tumors/carcinomas. Neuroendocrinology 2006;84:158–164.
26.
De Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O’Toole D, Ferone D, Frascati Consensus Conference, European Neuroendocrine Tumor Society: Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006;84:183–188.
27.
O’Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder W, Hyrdel R, Nikou G, Drenning E, Vullierme M, Caplin M, Jensen R, Eriksson B: Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006;84:189–195.
28.
Lepage C, Rachet B, Coleman MP: Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007;132:899–904.
29.
Mignon M: Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62(suppl 1):51–58.
30.
Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D, Jarzab B, Królicki L, Krzakowski M, Kunikowska J, Nasierowska-Guttmejer A, Nowak A, Rydzewska G, Starzyńska T, Szawłowski A, Round Table Conference participants: Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors). Endokrynol Pol 2008;59:41–56.
31.
Srirajaskanthan R, McStay M, Toumpanakis C, Meyer T, Caplin ME: Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology 2009;89:48–55.
32.
Reubi JC: Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80:51–56.
33.
Amthauer H, Denecke T, Rohlfing T, Ruf J, Böhmig M, Gutberlet M, Plöckinger U, Felix R, Lemke AJ: Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Eur Radiol 2005;15:1456–1462.
34.
Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, Rougier P, Duron F, Bouchard P, Grangé JD, Houry S, Talbot JN: Impact of fluorodihydroxyphenylalanine-(18F) PET on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009;94:1295–1301.
35.
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ: Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447–2455.
36.
Debray MP, Geoffroy O, Laissy JP, Lebtahi R, Silbermann-Hoffman O, Henry-Feugeas MC, Cadiot G, Mignon M, Schouman-Claeys E: Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001;74:1065–1070.
37.
Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, Chosidow D, Faraggi M, Mignon M, Le Guludec D: Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40:1602–1608.
38.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–518.
39.
Rivera MP, Detterbeck F, Mehta AC: Diagnosis of lung cancer: the guidelines. Chest 2003;123(1 suppl):129S–136S.
40.
Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning E, de Herder W, Goede A, Caplin M, Oberg M, Reubi J, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 2004;80:395–424.
41.
Kaltsas G, Besser G, Grossman A: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511.
42.
Costa L, Major PP: Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009;6:163–174.
43.
Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA, Miller JI: The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001;119:14–18.
44.
Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB: Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008;15:701–720.
45.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP: Radiolabeled somatostatin analog [177 Lu-DOTA0,Tyr 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–2762.
46.
Chan JA, Kulke MH: Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2008;12:253–270.
47.
Oberg K, Eriksson B: Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005;19:265–276.
48.
Gkialas I, Iordanidou L, Galanakis I, Giannopoulos S: The use of radioisotopes for palliation of metastatic bone pain. J BUON 2008;13:177–183.
49.
Fairchild A, Chow E: Role of radiation therapy and radiopharmaceuticals in bone metastases. Curr Opin Support Palliat Care 2007;1:169–173.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
